Zyprexa Kit
Product Images NDC 61269-662

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 34 technical images submitted to the FDA as part of the official labeling for Zyprexa (NDC 61269-662). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by H2-pharma Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Relprevv F001 V1)

Figure 1 (Relprevv F001 V1)
An instructional illustration showing a gloved hand holding a syringe and injecting into a marked surface, likely demonstrating proper syringe use or injection technique.*
FDA Label Image

Figure 2 (Relprevv F002 V2)

Figure 2 (Relprevv F002 V2)
An instructional illustration showing a hand holding a small vial or ampule, likely related to the ZYPREXA Relprevv (Olanzapine pamoate) intramuscular injection kit by H2-Pharma LLC. The image demonstrates proper handling of the vial before administration.*
FDA Label Image

Figure 3 (Relprevv F003 V2)

Figure 3 (Relprevv F003 V2)
An instructional line drawing illustrating a hand holding a syringe and vial, showing the process of mixing or preparing the medication, likely related to the ZYPREXA Relprevv intramuscular injection kit.*
FDA Label Image

Chemical Structure (Relprevv F004 V1)

Chemical Structure (Relprevv F004 V1)
Chemical structure diagram of the active ingredient, olanzapine pamoate, showing its molecular components and arrangement.*
FDA Label Image

210 mg/vial Convenience Kit (Zyprexa Relprevv 210 mg Carton)

210 mg/vial Convenience Kit (Zyprexa Relprevv 210 mg Carton)
Packaging label for ZYPREXA Relprevv 210 mg/vial Single-Dose Vial Convenience Kit. The product contains olanzapine pamoate for extended release injectable suspension, administered intramuscularly. The kit label includes dosage form and strength details, usage instructions, and is labeled by H2-Pharma LLC.*
FDA Label Image

300 mg/vial Convenience Kit (Zyprexa Relprevv 300 mg Carton)

300 mg/vial Convenience Kit (Zyprexa Relprevv 300 mg Carton)
The packaging label for ZYPREXA Relprevv (Olanzapine) Extended Release Injectable Suspension kit features a 300 mg/vial single-dose vial convenience kit. The label indicates intramuscular route and includes medication guide details. The product is presented by Cheplapharm and specifies use for deep intramuscular gluteal injection only.*
FDA Label Image

405 mg/vial Convenience Kit (Zyprexa Relprevv 405 mg Carton)

405 mg/vial Convenience Kit (Zyprexa Relprevv 405 mg Carton)
ZYPREXA Relprevv (Olanzapine) 405 mg/vial Single-Dose Vial Convenience Kit packaging label. The label shows it is for extended release injectable suspension, intended for intramuscular use. The kit is distributed by H2-Pharma LLC, with instructions noting it is for deep intramuscular gluteal injection only. The package includes a single-dose vial containing 405 mg/vial of Olanzapine pamoate.*
FDA Label Image
Figure (Zr Cp Logo)
FDA Label Image

Figure (Zr Needle Um F1 V3)

Figure (Zr Needle Um F1 V3)
An instructional illustration showing two figures: Fig. 1 depicts a hand inserting or positioning a syringe at an angle, and Fig. 2 shows a hand holding the syringe in a different orientation, likely related to the preparation or administration of the injectable drug ZYPREXA Relprevv (Olanzapine pamoate) kit for intramuscular use.*
FDA Label Image

Figure (Zr Needle Um F3 V1)

Figure (Zr Needle Um F3 V1)
Illustration showing a hand holding a syringe with a needle. The text reads 'KEEP NEEDLE IN VIEW,' indicating an instruction related to syringe handling or injection technique.*
FDA Label Image

Figure 2 (Zr Um Exclamation)

Figure 2 (Zr Um Exclamation)
ZYPREXA Relprevv kit packaging label displaying the brand name ZYPREXA Relprevv and the generic name Olanzapine pamoate. The label indicates that the product is a human prescription drug intended for intramuscular use. The labeler is listed as H2-Pharma LLC.*
FDA Label Image

Figure 1 (Zr Um F1 V1)

Figure 1 (Zr Um F1 V1)
Image showing the contents of the ZYPREXA Relprevv Olanzapine pamoate intramuscular injection kit. It includes two glass vials with labels, one containing the medication and the other a diluent, along with three orange-capped syringe components arranged beside the vials. This convenience kit is labeled by H2-Pharma LLC.*
FDA Label Image

Figure (Zr Um F10 V1)

Figure (Zr Um F10 V1)
ZYPREXA Relprevv kit packaging for Olanzapine pamoate, a human prescription drug labeled by H2-Pharma LLC. The image depicts the external box of the intramuscular injection kit, featuring branding and product information in a color scheme primarily including white and blue. The packaging is rectangular, showing the proprietary name prominently.*
FDA Label Image

Figure (Zr Um F11 V1)

Figure (Zr Um F11 V1)
ZYPREXA Relprevv kit packaging label showing the brand name prominently. The label indicates the product contains olanzapine pamoate for intramuscular use. The label includes instructions and warnings in black text on a white background, with some highlighted elements in yellow and purple. The kit is labeled by H2-Pharma LLC.*
FDA Label Image

Figure (Zr Um F12 V1)

Figure (Zr Um F12 V1)
ZYPREXA Relprevv kit packaging label displaying the brand name and the generic name Olanzapine pamoate. It is an intramuscular human prescription drug labeled by H2-Pharma LLC. The label design includes a boxed layout with the proprietary and generic names clearly visible.*
FDA Label Image

Figure (Zr Um F13 V1)

Figure (Zr Um F13 V1)
Packaging label of ZYPREXA Relprevv Kit containing Olanzapine pamoate for intramuscular use. The label displays the brand name ZYPREXA Relprevv along with the generic name Olanzapine pamoate. The kit is labeled as a human prescription drug, with the labeler noted as H2-Pharma LLC.*
FDA Label Image

Figure (Zr Um F14 V1)

Figure (Zr Um F14 V1)
ZYPREXA Relprevv KIT packaging label for Olanzapine pamoate. The label includes the proprietary name 'ZYPREXA Relprevv' and indicates its use as a human prescription drug in intramuscular dosage form. The labeler is H2-Pharma LLC. The packaging design is primarily white with some blue accents.*
FDA Label Image

Figure (Zr Um F15 V1)

Figure (Zr Um F15 V1)
The packaging label shows ZYPREXA Relprevv, an intramuscular kit containing Olanzapine pamoate. The label features a predominantly white background with a color-coded design element in blue, orange, and red stripes. The label includes barcoding and other standard packaging information. The labeler is H2-Pharma LLC.*
FDA Label Image

Figure (Zr Um F16 V1)

Figure (Zr Um F16 V1)
ZYPREXA Relprevv Olanzapine pamoate intramuscular injection kit packaging. The image shows a white and blue carton labeled with the brand name ZYPREXA Relprevv and indicates it is a kit. The labeler is H2-Pharma LLC. Specific dosage or quantity details are not visible.*
FDA Label Image

Figure (Zr Um F17 V1)

Figure (Zr Um F17 V1)
Packaging label for ZYPREXA Relprevv, an olanzapine pamoate intramuscular injection kit. The label displays the product and generic names prominently with the route of administration indicated. The labeler is H2-Pharma LLC. The kit format is shown, suitable for human prescription use.*
FDA Label Image

Figure (Zr Um F18 V1)

Figure (Zr Um F18 V1)
ZYPREXA Relprevv kit packaging label featuring the proprietary name and generic name Olanzapine pamoate. The label shows dosage form as intramuscular injection and the labeler as H2-Pharma LLC. The packaging is white with a light blue geometric design.*
FDA Label Image

Figure (Zr Um F19 V1)

Figure (Zr Um F19 V1)
ZYPREXA Relprevv kit packaging label showing the proprietary name and dosage form as intramuscular injection. The label includes the active ingredient, Olanzapine pamoate, and identifies the labeler as H2-Pharma LLC. The box appears primarily yellow with red and black text.*
FDA Label Image

Table (Zr Um F2 V1)

Table (Zr Um F2 V1)
A data table showing dosage information for ZYPREXA Relprevv (Olanzapine pamoate) intramuscular kit. It lists dose options (150 mg, 210 mg, 300 mg, 405 mg), corresponding vial strengths, and the required volume of diluent to add for each dose, ranging from 1.3 mL to 2.3 mL.*
FDA Label Image

Figure (Zr Um F20 V1)

Figure (Zr Um F20 V1)
ZYPREXA Relprevv kit packaging featuring the proprietary name and labeled for intramuscular use. The box is primarily white with black text and contains the nonproprietary name Olanzapine pamoate. The labeler is H2-Pharma LLC.*
FDA Label Image

Figure (Zr Um F21 V1)

Figure (Zr Um F21 V1)
ZYPREXA Relprevv kit packaging label for olanzapine pamoate. The label shows the product name, dosage form as intramuscular kit, and labeler H2-Pharma LLC on a white background with dark and yellow accents.*
FDA Label Image

Figure (Zr Um F22 V1)

Figure (Zr Um F22 V1)
ZYPREXA Relprevv is an intramuscular injection kit containing Olanzapine pamoate. The packaging shows the product name prominently with dosage form KIT and route INTRAMUSCULAR indicated. It is labeled by H2-Pharma LLC and includes instructions and components visible in the kit box.*
FDA Label Image

Figure 4 (Zr Um F3 V1)

Figure 4 (Zr Um F3 V1)
Illustration showing a gloved hand holding a vial labeled ZYPREXA Relprevv (Olanzapine pamoate) injectable, tapping it firmly to mix the contents before administration. The vial rests on a white absorbent pad.*
FDA Label Image

Figure (Zr Um F4 V1)

Figure (Zr Um F4 V1)
An instructional illustration shows two vials of ZYPREXA Relprevv (Olanzapine pamoate) injection kit held by a gloved hand. The top image shows a vial labeled 'Unsuspended: visible clumps,' while the bottom image shows a vial labeled 'Suspended: no clumps.' The figure advises checking for unsuspended powder and repeating tapping if needed to ensure proper suspension before use.*
FDA Label Image

Figure (Zr Um F5 V1)

Figure (Zr Um F5 V1)
An instructional image showing a gloved hand holding and vigorously shaking a small vial with a yellow cap and a label. This visual demonstrates proper preparation technique for ZYPREXA Relprevv (olanzapine pamoate) injectable kit.*
FDA Label Image

Figure (Zr Um F6 V1)

Figure (Zr Um F6 V1)
A data table showing dose-to-volume conversion for ZYPREXA Relprevv (Olanzapine pamoate) intramuscular injection. It lists four dose amounts (150 mg, 210 mg, 300 mg, 405 mg) alongside their corresponding final injection volumes (1 mL, 1.4 mL, 2 mL, 2.7 mL).*
FDA Label Image

Figure (Zr Um F7 V1)

Figure (Zr Um F7 V1)
ZYPREXA Relprevv kit for intramuscular injection containing Olanzapine pamoate, presented in professional packaging. The label shows the product name prominently with the active ingredient listed, designed for prescription use by H2-Pharma LLC.*
FDA Label Image

Figure (Zr Um F8 V1)

Figure (Zr Um F8 V1)
FDA Label Image

Figure (Zr Um F9 V1)

Figure (Zr Um F9 V1)
ZYPREXA Relprevv kit packaging for intramuscular injection. The label shows the proprietary name ZYPREXA Relprevv and the generic name Olanzapine pamoate. The product is identified as a human prescription drug and is labeled by H2-Pharma LLC. The image depicts the front of a small pharmaceutical kit box.*
FDA Label Image

Figure (Zr Um Logo V1)

Figure (Zr Um Logo V1)
ZYPREXA Relprevv kit packaging for Olanzapine pamoate extended release injectable suspension. The label displays the proprietary name alongside the generic name, indicating it is for intramuscular use. The labeler is H2-Pharma LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.